Collegium Pharmaceutical (COLL) EBITDA (2014 - 2026)

Collegium Pharmaceutical has reported EBITDA for 13 years, with the latest figure at $5.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 84.8% year-over-year to $5.5 million in Q2 2026; TTM through Jun 2026 was $159.7 million, a 21.02% increase from a year earlier, with the FY2025 full-year figure at $183.8 million, up 5.79% from the prior year.
• EBITDA was $5.5 million for Q2 2026 at Collegium Pharmaceutical, down from $31.4 million in the prior quarter.
• The five-year high for EBITDA was $62.1 million in Q3 2025, with the low at -$10.0 million in Q1 2022.
• Average EBITDA over 5 years is $32.7 million, with a median of $35.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 147.26% in 2022, then soared 424.69% in 2023.
• Over 5 years, EBITDA stood at $11.8 million in 2022, then jumped by 424.69% to $61.7 million in 2023, then tumbled by 38.22% to $38.1 million in 2024, then soared by 59.42% to $60.8 million in 2025, then sank by 90.93% to $5.5 million in 2026.
• The last three EBITDA figures came in at $5.5 million (Q2 2026), $31.4 million (Q1 2026), and $60.8 million (Q4 2025), per Business Quant data.